Arpida Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 30

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Arpida General Information

Description

Developer of antimicrobial drugs designed to treat infectious and bacterial diseases. The company develops drugs that include an antibiotic product that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant, enabling patients to get treatment and recover quickly.

Contact Information

Website
www.arpida.ch
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Duggingerstrasse 23
  • 4153 Reinach
  • Switzerland
+41 061
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
EvoNext Holdings
Vertical(s)
Life Sciences
Corporate Office
  • Duggingerstrasse 23
  • 4153 Reinach
  • Switzerland
+41 061

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arpida Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 11-Dec-2009 Completed Generating Revenue
5. IPO 27-Apr-2005 Completed Generating Revenue
4. Later Stage VC (Series C) 12-May-2004 Completed Product Development
3. Early Stage VC 08-Nov-2000 Completed Product Development
2. Early Stage VC 01-Jul-1998 $10M $10M Completed Product Development
1. University Spin-Out 01-Jan-1997 Completed Startup
To view Arpida’s complete valuation and funding history, request access »

Arpida Patents

  • 83

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Arpida Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090253722-A1 Aqueous pharmaceutical formulation Active 08-Apr-2008
US-7947293-B2 Aqueous pharmaceutical formulation Inactive 08-Apr-2008
WO-2009124586-A1 Aqueous pharmaceutical formulation Inactive 08-Apr-2008
AU-2006326354-A1 Diphenyl urea derivatives Inactive 13-Dec-2005
AU-2006326354-A8 Diphenyl urea derivatives Inactive 13-Dec-2005 C07C335/16
To view Arpida’s complete patent history, request access »

Arpida Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arpida Former Investors (29)

Investor Name Investor Type Holding Investor Since Participating Rounds
3i Group PE/Buyout Minority
Alta Berkeley Venture Capital Minority
Aventic Partners PE/Buyout Minority
BioCapital Investments Limited Partner Minority
BioMedPartners Venture Capital Minority
You’re viewing 5 of 29 investors. Get the full list »

Arpida Acquisitions (3)

Arpida’s most recent deal was a Reverse Merger with EvoNext Holdings. The deal was made on 11-Dec-2009.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EvoNext Holdings 11-Dec-2009 Reverse Merger Biotechnology
TLT Medical 13-Aug-2007 Merger/Acquisition Therapeutic Devices
Combio 15-Oct-2004 Merger/Acquisition Drug Discovery
To view Arpida’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Arpida FAQs

  • When was Arpida founded?

    Arpida was founded in 1997.

  • Where is Arpida headquartered?

    Arpida is headquartered in Reinach, Switzerland.

  • What is the size of Arpida?

    Arpida has 30 total employees.

  • What industry is Arpida in?

    Arpida’s primary industry is Drug Discovery.

  • Is Arpida a private or public company?

    Arpida is a Private company.

  • What is Arpida’s current revenue?

    The current revenue for Arpida is .

  • How much funding has Arpida raised over time?

    Arpida has raised $195M.

  • Who are Arpida’s investors?

    3i Group, Alta Berkeley, Aventic Partners, BioCapital Investments, and BioMedPartners are 5 of 29 investors who have invested in Arpida.

  • When was Arpida acquired?

    Arpida was acquired on 11-Dec-2009.

  • Who acquired Arpida?

    Arpida was acquired by EvoNext Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process